Recent advances in the understanding of severe cutaneous adverse reactions.
Nikki R AdlerA K AungE N ErgenJ TrubianoM S Y GohE J PhillipsPublished in: The British journal of dermatology (2017)
Severe cutaneous adverse reactions (SCARs) encompass a heterogeneous group of delayed hypersensitivity reactions, which are most frequently caused by drugs. Our understanding of several aspects of SCAR syndromes has evolved considerably over the last decade. This review explores evolving knowledge of the immunopathogenic mechanisms, pharmacogenomic associations, in vivo and ex vivo diagnostics for causality assessment, and medication cross-reactivity data related to SCAR syndromes. Given the rarity and severity of these diseases, multidisciplinary collaboration through large international, national and/or multicentre networks to collect prospective data on patients with SCAR syndromes should be prioritized. This will further enhance a systematized framework for translating epidemiological, clinical and immunopathogenetic advances into preventive efforts and improved outcomes for patients.
Keyphrases
- adverse drug
- quality improvement
- drug induced
- electronic health record
- end stage renal disease
- healthcare
- newly diagnosed
- ejection fraction
- early onset
- big data
- chronic kidney disease
- wound healing
- randomized controlled trial
- type diabetes
- study protocol
- cross sectional
- clinical decision support
- artificial intelligence
- double blind
- patient reported